Pmv Pharmaceuticals Inc

Company Profile

Pmv Pharmaceuticals Inc had its IPO on 2020-09-25 under the ticker symbol PMVP.

The company operates in the Healthcare sector and Biotechnology industry. Pmv Pharmaceuticals Inc has a staff strength of 62 employees.

Stock update

Shares of Pmv Pharmaceuticals Inc opened at $6.18 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.1 - $6.44, and closed at $6.4.

This is a +3.9% increase from the previous day's closing price.

A total volume of 691,969 shares were traded at the close of the day’s session.

In the last one week, shares of Pmv Pharmaceuticals Inc have slipped by -12.57%.

Pmv Pharmaceuticals Inc's Key Ratios

Pmv Pharmaceuticals Inc has a market cap of $354.69 million, indicating a price to book ratio of 1.6976 and a price to sales ratio of 0.

In the last 12-months Pmv Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-81450000. The EBITDA ratio measures Pmv Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Pmv Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -18.92% with a return of equity of -29.97%.

In Q2, Pmv Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Pmv Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.59 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pmv Pharmaceuticals Inc’s profitability.

Pmv Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.6621. Its price to sales ratio in the trailing 12-months stood at 0.

Pmv Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$242.22 million

Total Liabilities

$11.45 million

Operating Cash Flow

$0

Capital Expenditure

$565000

Dividend Payout Ratio

0%

Pmv Pharmaceuticals Inc ended 2024 with $242.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $242.22 million while shareholder equity stood at $217.81 million.

Pmv Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $11.45 million in other current liabilities, in common stock, $-277607000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $68.21 million and cash and short-term investments were $187.09 million. The company’s total short-term debt was $18,000 while long-term debt stood at $0.

Pmv Pharmaceuticals Inc’s total current assets stands at $190.41 million while long-term investments were $31.76 million and short-term investments were $118.88 million. Its net receivables were $0 compared to accounts payable of $3.49 million and inventory worth $0.

In 2024, Pmv Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $565000.

Comparatively, Pmv Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$6.4

52-Week High

$13.76

52-Week Low

$3.84

Analyst Target Price

$21.5

Pmv Pharmaceuticals Inc stock is currently trading at $6.4 per share. It touched a 52-week high of $13.76 and a 52-week low of $13.76. Analysts tracking the stock have a 12-month average target price of $21.5.

Its 50-day moving average was $7.02 and 200-day moving average was $6.79 The short ratio stood at 11.76 indicating a short percent outstanding of 0%.

Around 211.9% of the company’s stock are held by insiders while 11855.5% are held by institutions.